Literature DB >> 25388964

sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia.

S Colafrancesco1, R Priori, C Alessandri, E Astorri, C Perricone, M Blank, N Agmon-Levin, Y Shoenfeld, G Valesini.   

Abstract

Ferritin has a key role in Adult-onset Still's disease (AOSD). Its production seems related to macrophage activation of which sCD163 is a major serum marker. Thus, we aimed at evaluating the role of sCD163 in AOSD and its relationship with ferritin. Furthermore, we determined the expression of CD163 and ferritin in a lymph-node from an AOSD patient. sCD163 and serum ferritin were measured in 34 patients with AOSD (21 active, 13 non-active), 18 sepsis and 22 healthy controls (HC). Immunohistology was performed on a lymph-node from an AOSD patient in order to detect CD163 and ferritin. A tonsil from an HC was used as control. Mean sCD163 (8.6 ± 5.4 mg/L) was higher in active AOSD than "non-active" patients (4.6 ± 2.7 mg/L, p = 0.02). The mean sCD163 in AOSD (6.9 ± 4.9 mg/L) and sepsis (7.1 ± 5.6 mg/L) were higher than in HC (2.56 ± 1.17 mg/L, p < 0.001), but no difference between AOSD and sepsis was detected. sCD163 positively correlated with ferritin (p = 0.0045; r = 0.4755) only in AOSD. Serum ferritin (mean 3,640.1 ± 6,896.9 µg/L) was higher in active AOSD than in sepsis (1,720.2 ± 3,882.1 µg/L, p < 0.007). CD163 was equally distributed in the B and T areas of both lymph-node and tonsil. Differently from the tonsil, ferritin was expressed only in the lymph-node B area. sCD163 is a marker of disease activity in AOSD. The correlation with ferritin may lead to hypothesize a macrophage activation related to hyperferritinemia. Ferritin was found expressed only in the B area of the AOSD lymph-node, suggesting a role for this molecule as an antigen in the disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25388964     DOI: 10.1007/s12026-014-8563-7

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  24 in total

Review 1.  Soluble CD163.

Authors:  Holger J Møller
Journal:  Scand J Clin Lab Invest       Date:  2011-11-07       Impact factor: 1.713

2.  Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome.

Authors:  Dominik J Schaer; Boris Schleiffenbaum; Michael Kurrer; Alexander Imhof; Esther Bächli; Jörg Fehr; Holger J Moller; Soren K Moestrup; Andreas Schaffner
Journal:  Eur J Haematol       Date:  2005-01       Impact factor: 2.997

3.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

4.  Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis.

Authors:  Monika Rau; Martin Schiller; Stefan Krienke; Petra Heyder; Hannes Lorenz; Norbert Blank
Journal:  J Rheumatol       Date:  2010-09-01       Impact factor: 4.666

5.  Interleukin 18: a biomarker for differential diagnosis between adult-onset Still's disease and sepsis.

Authors:  Roberta Priori; Serena Colafrancesco; Cristiano Alessandri; Antonina Minniti; Carlo Perricone; Giancarlo Iaiani; Donatella Palazzo; Guido Valesini
Journal:  J Rheumatol       Date:  2014-05-01       Impact factor: 4.666

6.  The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.

Authors:  Jack Bleesing; Anne Prada; David M Siegel; Joyce Villanueva; Judyann Olson; Norman T Ilowite; Hermine I Brunner; Thomas Griffin; Thomas B Graham; David D Sherry; Murray H Passo; Athimalaipet V Ramanan; Alexandra Filipovich; Alexei A Grom
Journal:  Arthritis Rheum       Date:  2007-03

Review 7.  Ferritin in autoimmune diseases.

Authors:  Gisele Zandman-Goddard; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2007-02-16       Impact factor: 9.754

Review 8.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  IL-18 Serum Level in Adult Onset Still's Disease: A Marker of Disease Activity.

Authors:  Serena Colafrancesco; Roberta Priori; Cristiano Alessandri; Carlo Perricone; Monica Pendolino; Giovanna Picarelli; Guido Valesini
Journal:  Int J Inflam       Date:  2012-06-18

Review 10.  The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome.

Authors:  Cristina Rosário; Gisele Zandman-Goddard; Esther G Meyron-Holtz; David P D'Cruz; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-08-22       Impact factor: 8.775

View more
  26 in total

1.  The CD68(+)/H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis.

Authors:  P Ruscitti; F Ciccia; P Cipriani; G Guggino; P Di Benedetto; A Rizzo; V Liakouli; O Berardicurti; F Carubbi; G Triolo; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2015-12-08       Impact factor: 4.330

2.  Elevated serum levels of interleukin-10 in adult-onset Still's disease are associated with disease activity.

Authors:  Yue Sun; Zhihong Wang; Huihui Chi; Qiongyi Hu; Junna Ye; Honglei Liu; Xiaobing Cheng; Hui Shi; Zhuochao Zhou; Jialin Teng; Chengde Yang; Yutong Su
Journal:  Clin Rheumatol       Date:  2019-06-21       Impact factor: 2.980

3.  Introduction to the special issue on the 9th International Congress on Autoimmunity.

Authors:  Eric Rosenthal; Mathilde Versini; Pierre-Yves Jeandel; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 4.  Pediatric Multiple Organ Dysfunction Syndrome: Promising Therapies.

Authors:  Allan Doctor; Jerry Zimmerman; Michael Agus; Surender Rajasekaran; Juliane Bubeck Wardenburg; James Fortenberry; Anne Zajicek; Emma Mairson; Katri Typpo
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

Review 5.  Hyperferritinemia and inflammation.

Authors:  Kate F Kernan; Joseph A Carcillo
Journal:  Int Immunol       Date:  2017-11-01       Impact factor: 4.823

6.  H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome.

Authors:  P Ruscitti; P Cipriani; P Di Benedetto; V Liakouli; O Berardicurti; F Carubbi; F Ciccia; G Guggino; G Triolo; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

7.  H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease.

Authors:  P Ruscitti; P Cipriani; F Ciccia; P Di Benedetto; V Liakouli; O Berardicurti; F Carubbi; G Guggino; S Di Bartolomeo; G Triolo; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

8.  Elevated serum gasdermin D N-terminal implicates monocyte and macrophage pyroptosis in adult-onset Still's disease.

Authors:  Hideto Nagai; Yohei Kirino; Hiroto Nakano; Yosuke Kunishita; Riko Henmi; Ann Marie Szymanski; Ryusuke Yoshimi; Michael J Ombrello; Hideaki Nakajima
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

Review 9.  Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates.

Authors:  Sajad Fakhri; Zeinab Nouri; Seyed Zachariah Moradi; Esra Küpeli Akkol; Sana Piri; Eduardo Sobarzo-Sánchez; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

Review 10.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.